Hypothetical case - For market research purposes only

The DREAMM-2 Clinical Trial

Learn about DREAMM-2, which evaluated the efficacy and safety of belantamab mafodotin-blmf in patients with relapsed or refractory multiple myeloma including failure to prior treatment with an anti-CD38 antibody.